WithdrawnNCT05062577
Safety study of Safety and Efficacy of ASP8062 in Addiction
Medication studyAges 18–65
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 8, 2021
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Astellas Pharma Global Development, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05062577
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Recruitment & locations
WithdrawnLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Astellas Pharma Global Development, Inc., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including ASP8062, Placebo ASP8062 and buprenorphine/naloxone.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
